Skip to main content
. 2016 Sep 2;5(10):e1221555. doi: 10.1080/2162402X.2016.1221555

Figure 3.

Figure 3.

Kaplan–Meier analysis of biochemical recurrence (BRC)-free survival in 417 prostate cancer patients stratified by PD-1 DNA methylation status. Patient classification into mPD-1high and mPD-1low cases was based on an optimized cut-off (57.50% methylation) as shown in Fig. 2. Approximate mean BCR-free survival: 92 months (mPD-1low, 95%CI: 84–100 months, n = 239) and 79 months (mPD-1high, 95%CI: 67–90, n = 178; p = 0.002), respectively.